 |
Our strategy is to focus exclusively on Rx and OTC cough products that can be developed and approved using only pharmacokinetic studies. This strategy lowers costs, risks and time to market. Importantly, we have developed a number of patent applications that will provide long term protection to our approved products. Recently, we have begun work on an Rx-to-OTC switch that could achieve sales in excess of $200M.
|
|
|